Association of Polymorphisms in Pharmacogenetic Candidate Genes (OPRD1, GAL, ABCB1, OPRM1) with Opioid Dependence in European Population: A Case-Control Study

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Beer, Beate ^a   Erb, Robert ^a   Pavlic, Marion ^a   Ulmer, Hanno ^a   Giacomuzzi, Salvatore ^a   Riemer, Yvonne ^a   Oberacher, Herbert ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; DELTA OPIATE RECEPTOR; DNA; GALANIN; METHADONE; MU OPIATE RECEPTOR; MULTIDRUG RESISTANCE PROTEIN 1; OPIATE;

ABCB1 GENE; ADULT; ARTICLE; CASE CONTROL STUDY; CAUCASIAN; CONTROLLED STUDY; DNA EXTRACTION; FEMALE; GAL GENE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; OPIATE ADDICTION; OPRD1 GENE; OPRM1 GENE; PATHOGENESIS; PHARMACOGENETICS; PHENOTYPE; POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; EUROPE; GALANIN; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; MASS SPECTROMETRY; ODDS RATIO; OPIOID-RELATED DISORDERS; P-GLYCOPROTEIN; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, MU;

EID: 84884559745     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075359     Document Type: Article

References (44)

1. Ho MK, Goldman D, Heinz A, Kaprio J, Kreek MJ, et al. (2011) Breaking barriers in the genomics and pharmacogenetics of drug addiction. Clin Pharmacol Ther 88: 779-791. PubMed: 20981002.
2. Yuferov V, Levran O, Proudnikov D, Nielsen DA, Kreek MJ, (2010) Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment. Ann N Y Acad Sci 1187: 184-207. doi:10.1111/j.1749-6632.2009.05275.x. PubMed: 20201854.
3. Goldman D, Oroszi G, Ducci F, (2005) The genetics of addictions: uncovering the genes. Nat Rev Genet 6: 521-532. doi:10.1038/nrn1700. PubMed: 15995696.
4. Li MD, Burmeister M, (2009) New insights into the genetics of addiction. Nat Rev Genet 10: 225-231. doi:10.1038/ni0309-225. PubMed: 19238175.
5. Kreek MJ, Bart G, Lilly C, LaForge KS, Nielsen DA, (2005) Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacol Rev 57: 1-26. doi:10.1124/pr.57.1.1. PubMed: 15734726.
6. Kreek MJ, Nielsen DA, Butelman ER, LaForge KS, (2005) Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction. Nat Neurosci 8: 1450-1457. doi:10.1038/nn1583. PubMed: 16251987.
7. Levran O, Londono D, O'Hara K, Nielsen DA, Peles E, et al. (2008) Genetic susceptibility to heroin addiction: a candidate gene association study. Genes Brain Behav 7: 720-729. doi:10.1111/j.1601-183X.2008.00410.x. PubMed: 18518925.
8. Levran O, Yuferov V, Kreek MJ, (2013) The genetics of the opioid system and specific drug addictions. Hum Genet 131: 823-842. PubMed: 22547174.
9. Mroziewicz M, Tyndale RF, (2010) Pharmacogenetics: a tool for identifying genetic factors in drug dependence and response to treatment. Addict Sci Clin Pract 5: 17-29. PubMed: 22002450.
10. Brandstätter A, Niederstätter H, Pavlic M, Grubwieser P, Parson W, (2007) Generating population data for the EMPOP database- an overview of the mtDNA sequencing and data evaluation processes considering 273 Austrian control region sequences as example. Forensic Sci Int 166: 164-175. doi:10.1016/j.forsciint.2006.05.006. PubMed: 16829006.
11. Kadiev E, Patel V, Rad P, Thankachan L, Tram A, et al. (2008) Role of pharmacogenetics in variable response to drugs: focus on opioids. Expert Opin Drug Metab Toxicol 4: 77-91. doi:10.1517/17425255.4.1.77. PubMed: 18370860.
12. Lötsch J, Geisslinger G, Tegeder I, (2009) Genetic modulation of the pharmacological treatment of pain. Pharmacol Ther 124: 168-184. doi:10.1016/j.pharmthera.2009.06.010. PubMed: 19615406.
13. Terman GW, Jin W, Cheong YP, Lowe J, Caron MG, (2004) G-protein receptor kinase 3 (GRK3) influences opioid analgesic tolerance but not opioid withdrawal. Br J Pharmacol 141: 55-64. doi:10.1038/sj.bjp.0705595. PubMed: 14662727.
14. Vandenbergh DJ, Rodriguez LA, Miller IT, Uhl GR, Lachman HM, (1997) High-activity catechol-O-methyltransferase allele is more prevalent in polysubstance abusers. Am J Med Genet 74: 439-442. doi:10.1002/(SICI)1096-8628(19970725)74:4. PubMed: 9259381.
15. Hung CC, Chiou MH, Huang BH, Hsieh YW, Hsieh TJ, et al. (2011) Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients. Pharmacogenomics 12: 1525-1533. doi:10.2217/pgs.11.96. PubMed: 21902500.
16. Li T, Liu X, Zhao J, Hu X, Ball DM, et al. (2002) Allelic association analysis of the dopamine D2, D3, 5-HT2A, and GABA(A)gamma2 receptors and serotonin transporter genes with heroin abuse in Chinese subjects. Am J Med Genet 114: 329-335. doi:10.1002/ajmg.10200. PubMed: 11920858.
17. Beer B, Erb R, Pitterl F, Niederstätter H, Maroñas O, et al. (2011) CYP2D6 genotyping by liquid chromatography-electrospray ionisation mass spectrometry. Anal Bioanal Chem 400: 2361-2370. doi:10.1007/s00216-010-4597-4. PubMed: 21225252.
18. Oberacher H, Niederstätter H, Casetta B, Parson W, (2005) Detection of DNA sequence variations in homo- and heterozygous samples via molecular mass measurements by electrospray ionization time-of-flight mass spectrometry. Anal Chem 77: 4999-5008. doi:10.1021/ac050399f. PubMed: 16053315.
19. Beer B, Krjutškov K, Erb R, Viltrop T, Oberacher H, (2012) A novel amplification strategy for genotyping with liquid chromatography-electrospray ionization mass spectrometry. Analyst 137: 5325-5333. doi:10.1039/c2an35440c. PubMed: 23034565.
20. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, et al. (2001) Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70: 189-199. doi:10.1067/mcp.2001.117412. PubMed: 11503014.
21. Farré M, Mas A, Torrens M, Moreno V, Camí J, (2002) Retention rate and illicit opioid use during methadone maintenance interventions: a meta-analysis. Drug Alcohol Depend 65: 283-290. doi:10.1016/S0376-8716(01)00171-5. PubMed: 11841899.
22. Le Merrer J, Becker JA, Befort K, Kieffer BL, (2009) Reward processing by the opioid system in the brain. Physiol Rev 89: 1379-1412. doi:10.1152/physrev.00005.2009. PubMed: 19789384.
23. Nelson EC, Lynskey MT, Heath AC, Wray N, Agrawal A, et al. (2012) Association of OPRD1 polymorphisms with heroin dependence in a large case-control series. Addict Biol. doi:10.1111/j.1369-1600.2012.00445.x.
24. Zhang H, Kranzler HR, Yang BZ, Luo X, Gelernter J, (2008) The OPRD1 and OPRK1 loci in alcohol or drug dependence: OPRD1 variation modulates substance dependence risk. Mol Psychiatry 13: 531-543. doi:10.1038/sj.mp.4002035. PubMed: 17622222.
25. Picciotto MR, (2010) Galanin and addiction. EXS 102: 195-208. PubMed: 21299070.
26. Arias-Carrión O, Salama M, (2012) Reward-seeking behavior and addiction: cause or cog? Curr Drugs Abuse Rev 5: 178-189. doi:10.2174/1874473711205030178.
27. Unschuld PG, Ising M, Erhardt A, Lucae S, Kohli M, et al. (2008) Polymorphisms in the galanin gene are associated with symptom-severity in female patients suffering from panic disorder. J Affect Disord 105: 177-184. doi:10.1016/j.jad.2007.05.006. PubMed: 17573119.
28. Unschuld PG, Ising M, Roeske D, Erhardt A, Specht M, et al. (2010) Gender-specific association of galanin polymorphisms with HPA-axis dysregulation, symptom severity, and antidepressant treatment response. Neuropsychopharmacology 35: 1583-1592. doi:10.1038/npp.2010.30. PubMed: 20237460.
29. Cascorbi I, (2011) P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations. Handb Exp Pharmacol 201: 261-283. doi:10.1007/978-3-642-14541-4_6. PubMed: 21103972.
30. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, et al. (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 84: 7735-7738. doi:10.1073/pnas.84.21.7735. PubMed: 2444983.
31. Zheng H, Webber S, Zeevi A, Schuetz E, Zhang J, et al. (2002) The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients. Hum Immunol 63: 765-770. doi:10.1016/S0198-8859(02)00426-3. PubMed: 12175731.
32. Zhou SF, (2008) Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 38: 802-832. doi:10.1080/00498250701867889. PubMed: 18668431.
33. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, et al. (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 97: 3473-3478. doi:10.1073/pnas.97.7.3473. PubMed: 10716719.
34. Levran O, O'Hara K, Peles E, Li D, Barral S, et al. (2008) ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Hum Mol Genet 17: 2219-2227. doi:10.1093/hmg/ddn122. PubMed: 18424454.
35. Coller JK, Barratt DT, Dahlen K, Loennechen MH, Somogyi AA, (2006) ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clin Pharmacol Ther 80: 682-690. doi:10.1016/j.clpt.2006.09.011. PubMed: 17178268.
36. Fonseca F, de la Torre R, Díaz L, Pastor A, Cuyàs E, et al. (2011) Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response. PLOS ONE 6: e19527. doi:10.1371/journal.pone.0019527. PubMed: 21589866.
37. Crettol S, Déglon JJ, Besson J, Croquette-Krokar M, Hämmig R, et al. (2006) ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 80: 668-681. doi:10.1016/j.clpt.2006.09.012. PubMed: 17178267.
38. De Klerk OL, Bosker FJ, Luurtsema G, Nolte IM, Dierckx R, et al. (2011) The role of p-glycoprotein in psychiatric disorders: a reliable guard of the brain? 11Cent Nerv Syst Agents Med Chem. pp.: 197-209.
39. Fujii T, Ota M, Hori H, Sasayama D, Hattori K, et al. (2012) Association between the functional polymorphism (C3435T) of the gene encoding P-glycoprotein (ABCB1) and major depressive disorder in the Japanese population. J Psychiatr Res 46: 555-559. doi:10.1016/j.jpsychires.2012.01.012. PubMed: 22306099.
40. Gelernter J, Kranzler HR, (2010) Genetics of drug dependence. Dialogues Clin Neurosci 12: 77-84. PubMed: 20373669.
41. Bart G, Heilig M, LaForge KS, Pollak L, Leal SM, et al. (2004) Substantial attributable risk related to functional μ-opioid receptor gene polymorphism in association with heroin addiction in central Sweden. Mol Psychiatry 9: 547-549. doi:10.1038/sj.mp.4001504. PubMed: 15037869.
42. Huang CJ, Liu HF, Su NY, Hsu YW, Yang CH, et al. (2008) Association between human opioid receptor genes polymorphisms and pressure pain sensitivity in females. Anaesthesia 63: 1288-1295. doi:10.1111/j.1365-2044.2008.05760.x. PubMed: 19032295.
43. Zhang L, Kendler KS, Chen X, (2008) The mu-opioid receptor gene and smoking initiation and nicotine dependence. Behav Brain Funct 2: 28. PubMed: 16887046.
44. Hattersley AT, McCarthy MI, (2005) What makes a good genetic association study? Lancet 366: 1315-1323. doi:10.1016/S0140-6736(05)67531-9. PubMed: 16214603.